GlaxoSmithKline and Theravance announced that Breo Ellipta is now available in pharmacies for the long-term, once‐daily, maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema and to reduce exacerbations of COPD in patients with a history of exacerbations.

RELATED: Respiratory Disorders Resource Center

Breo Ellipta is a combination of the inhaled corticosteroid (ICS), fluticasone furoate 100mcg and the long-acting beta2-agonist (LABA), vilanterol 25mcg.  

The combination inhaler works by decreasing inflammation in the lungs and helping the muscles around the airways of the lungs stay relaxed to increase airflow and reduce exacerbations in patients with COPD.

Breo Ellipta dry powder inhaler is currently available in a 100mcg/25mcg strength. 

For more information visit and